News
GSK is acquiring an experimental medicine from a Cambridge biotech to shore up its drug pipeline and muscle into the ...
The research collaboration, under which Septerna will receive more than $200 million in upfront and near-term fees, is the ...
Roche is among several drugmakers to announce large-scale U.S. investments in response to Trump's push to onshore ...
During a live event, Shuo Ma, MD, PhD, discussed the resistance mutation analysis of patients who had disease progression ...
Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...
Hospital nurses immediately diagnosed Kelly with type 1 diabetes, a non-communicable disease (NCD), and put her on a treatment regimen that she will likely need to follow for the rest of her life.
Explore more
“The legacy I hope to build is one of freedom—freedom from anything that’s keeping you from becoming who you truly want to be in this life. I see so many people stuck in jobs they hate, or just living ...
U.S. President Donald Trump's executive order on drug pricing threatens Roche's planned $50 billion investment in the United ...
A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap, while ...
Treatment with JAK inhibitors was associated with a greater risk of infections compared with biologic therapies in patients with atopic dermatitis.
Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last ...
Currently trailing Eli Lilly and Structure Therapeutics in the oral weight loss space, Novo Nordisk strikes a deal with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results